COMP <GO>
EWTX vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Edgewise Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: EWTX 3
— LLY 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: EWTX
LAST: $38.11 (-2.03%) • MKT CAP: $4.22B
balance-sheet
26.00
LAST: $1,410.99 (-0.46%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | 32.36% | -64.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.41% | 2.30% | -5.71 | LLY | /fcf-yield <GO> |
| Operating Margin | -16.20% | 40.21% | -56.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 31.90% | -31.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 45.51% | -46.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 9.29 | +16.71 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 9/9 | -6.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.81% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 71.0 | -25.30 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.51 | +0.59 | EWTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 30.6x | -5.62 | EWTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.22B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | LLY REV | EWTX GROSS % | LLY GROSS % | EWTX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $535.9M | $65.18B | — | 83.0% | -$144.1M | $16.81B |
| FY 2024 | $444.7M | $45.04B | — | 81.3% | -$110.3M | $8.82B |
| FY 2023 | $320.2M | $34.12B | — | 79.3% | -$91.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
LLY // BETA 0.51